In HER2-positive cancers, amplification of the ERBB2 locus leads to marked overexpression of the HER2 receptor, driving constitutive activation of downstream cascades (PI3K/AKT and MAPK) that promote proliferation, survival, and apoptosis resistance. This evidence concerns the gene ERBB2 and cancer.